Cite
HARVARD Citation
Visvanathan, S. et al. (2019). Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Annals of the rheumatic diseases. 78 (6), pp. 754-760. [Online].